Rheumatoid arthritis: Biological therapy other than anti-TNF

International Immunopharmacology

Volumn 27, Issue 2, 2015, Pages 185-188

  Rossi, Daniela ^a   Modena, Vittorio ^a   Sciascia, Savino ^a   Roccatello, Dario ^a  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

Abatacept; Anti IL6; Rheumatoid arthritis; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LIPID; LIVER ENZYME; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; CELLULITIS; COMORBIDITY; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MONOTHERAPY; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RECOMMENDED DRUG DOSE; REMISSION; RHEUMATOID ARTHRITIS; TUBERCULOSIS; URINARY TRACT INFECTION; ARTHRITIS, RHEUMATOID;

ABATACEPT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; RITUXIMAB;

EID: 84937163911     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.03.019     Document Type: Review

References (49)

1. A.D. Bankhurst, G. Husby, and R.C. Williams Jr. Predominance of T cells in the lymphocytic infiltrates of synovial tissues in rheumatoid arthritis Arthritis Rheum. 19 3 1976 555 562
2. J.J. Cush, and P.E. Lipsky Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis Arthritis Rheum. 31 10 1988 1230 1238
3. R.I. Fox, S. Fong, N. Sabharwal, S.A. Carstens, P.C. Kung, and J.H. Vaughan Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis J. Immunol. 128 1 1982 351 354
4. J.A. Van Boxel, and S.A. Paget Predominantly T-cell infiltrate in rheumatoid synovial membranes N. Engl. J. Med. 293 11 1975 517 520
5. M.C. Boissier, L. Semerano, S. Challal, N. Saidenberg-Kermanac'h, and G. Falgarone Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction J Autoimmun. 39 2012 222 228
6. M. Chabaud, J.M. Durand, N. Buchs, F. Fossiez, G. Page, L. Frappart, and et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium Arthritis Rheum. 42 1999 963 970
7. L.W. Moreland, R. Alten, F. Van den Bosch, and et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum. 46 2002 1470 1479
8. U. Grohmann, R. Bianchi, C. Orabona, F. Fallarino, C. Vacca, A. Micheletti, and et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation J. Immunol. 171 2003 2581 2587
9. D.H. Munn, M.D. Sharma, and A.L. Mellor Ligation of B7-1/B7-2 by human CD4 + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells J. Immunol. 172 2004 4100 4110
10. J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy, and et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial Arthritis Rheum. 52 2005 2263 2271
11. J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, and et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann. Intern. Med. 144 2006 865 876
12. M. Schiff, M. Keiserman, C. Codding, S. Songcharoen, A. Berman, S. Nayiager, and et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann. Rheum. Dis. 67 2008 1096 1103
13. R. Westhovens, J.M. Kremer, P. Emery, A.S. Russell, R. Alten, E. Barré, and M. Dougados Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study Clin. Exp. Rheumatol. 32 2014 553 562
14. F. Atzeni, P. Sarzi-Puttini, C. Botsios, A. Carletto, P. Cipriani, E.G. Favalli, and et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry Autoimmun. Rev. 12 2012 225 229
15. F.B. Pallavicini, R. Caporali, P. Sarzi-Puttini, F. Atzeni, C. Bazzani, R. Gorla, and et al. Tumor necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry Autoimmun. Rev. 9 2010 175 180
16. I. Olivieri, P. Sarzi-Puttini, S. Bugatti, F. Atzeni, S. d'Angelo, and R. Caporali Early treatment in early undifferentiated arthritis Autoimmun. Rev. 11 2012 589 592
17. F. Atzeni, P. Sarzi-Puttini, R. Gorla, A. Marchesoni, and R. Caporali Switching rheumatoid arthritis treatments: an update Autoimmun. Rev. 10 2011 397 403
18. F. Atzeni, R. Talotta, M. Benucci, F. Salaffi, A. Cassinotti, V. Varisco, and et al. Immunogenicity and autoimmunity during anti-TNF therapy Autoimmun. Rev. 12 2013 703 770
19. M. Khraishi, A. Russell, and W.P. Olszynski Safety profile of abatacept in rheumatoid arthritis: a review Clin. Ther. 32 11 Oct 2010 855 870
20. J.D. Alves, A. Marinho, and M.J. Serra Tocilizumab: is there life beyond anti-TNF blockade? Int. J. Clin. Pract. 65 2011 508 513
21. L. Kaly, and I. Rosner Tocilizumab - a novel therapy for non-organ-specific auto-immune diseases Best Pract. Res. Clin. Rheumatol. 26 2012 157 165
22. P.P. Tak, and J.R. Kalden Advances in rheumatology: new targeted therapeutics Arthritis Res. Ther. 13 2011 S5
23. N. Nishimoto, K. Yoshizaki, K. Maeda, and et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study J. Rheumatol. 30 7 2003 1426 1435 (Phase I trial analyzing pharmacokinetics of tocilizumab (TCZ) in rheumatoid arthritis (RA) patients.)
24. N. Nishimoto, T. Kishimoto, and K. Yoshizaki Anti-interleukin 6 receptor antibody treatment in rheumatic disease Ann. Rheum. Dis. 59 2000 121 127
25. P.A. Guerne, B.L. Zuraw, J.H. Vaughan, and et al. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis J. Clin. Invest. 83 1989 585 9213
26. T. Hirano, T. Matsuda, M. Turner, and et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis Eur. J. Immunol. 18 1988 1797 1801
27. F.A. Houssiau, J.P. Devogelaer, J. van Damme, and et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides Arthritis Rheum. 31 1988 784 788
28. R. Madhok, A. Crilly, J. Watson, and H.A. Capell Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity Ann. Rheum. Dis. 52 1993 232 234
29. U. Sack, R.W. Kinne, T. Marx, and et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis Rheumatol. Int. 13 1993 45 51
30. S. Kotake, K. Sato, K.J. Kim, and et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J. Bone Miner. Res. 11 1996 88 95
31. M. Mihara, K. Kasutani, M. Okazaki, and et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int. Immunopharmacol. 5 12 2005 1731 1740
32. J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, and et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 9617 2008 987 997
33. Actemra Proscribing Information 2013 Genentech, Inc.; A Member of Roche Group South San Francisco, CA, USA (Revised)
34. J.S. Smolen, M.M. Schoels, N. Nishimoto, and et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions Ann. Rheum. Dis. 72 4 2013 482 492
35. European League Against Rheumatism (EULAR) Recommendations for Management Available from http://www.eular.org/index.cfm?framePage/recommendations-management.cfm (Accessed on September 22, 2014)
36. I. Al-Shakarchi, N.J. Gullick, and D.L. Scott Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review Patient Prefer. Adherence 7 2013 653 666
37. G.R. Burmester, A. Rubbert-Roth, A. Cantagrel, and et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) Ann. Rheum. Dis. 73 1 2014 69 74 (Phase III trial of TCZ evaluating the efficacy and safety of TCZ combination therapy by subcutaneous administration versus by intravenous administration in RA patients.)
38. G. Jones, A. Sebba, J. Gu, and et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann. Rheum. Dis. 69 1 2010 88 96 (Pivotal Phase III trial showing that TCZ monotherapy is superior to methotrexate (MTX).)
39. R. Alten, and T. Maleitzke Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic disease Ann. Med. 45 4 2013 357 363
40. L.M. Amezcua-Guerra, R. Springall, R. Marquez-Velasco, and et al. Presence against cyclic citrullinated peptides in patients with Rhupus: a cross-sectional study Arthritis Res. Ther. 8 5 2006 R144
41. M. Satoh, A.K. Ajmani, and M. Akizuki What is the definition for coexistent rheumatoid arthritis and systemic lupus erythematosus? Lupus 3 1994 137 138
42. Eilertsen, C. Nikolaisen, A. Becker-Merok, and J.C. Nossent Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus Lupus 20 2011 607 613
43. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
44. B. Marston, A. Palanichamy, and J.H. Anolik B cells in the pathogenesis and treatment of rheumatoid arthritis Curr. Opin. Rheumatol. 22 2010 307 315
45. J.C. Edwards, G. Cambridge, and M.J. Leandro B cell depletion therapy in rheumatic disease Best Pract. Res. Clin. Rheumatol. 20 2006 915e28
46. J.A. Markenson, A. Gibofsky, W.R. Palmer, and et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry J. Rheumatol. 38 2011 1273 1281
47. M. Sebastiani, M.G. Anelli, and F. Atzeni Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register Joint Bone Spine 81 2014 508 512
48. J. Sellam, H. Hendel-Chavez, S. Rouanet, and et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis Arthritis Rheum. 63 2001 933 938
49. J.D. Isaacs, S.B. Cohen, P. Emery, and et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis Ann. Rheum. Dis. 72 2013 329 336